{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:28:31Z","timestamp":1789579711169,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40262-020-00975-y","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:28:45Z","timestamp":1610497725000},"page":"665-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis"],"prefix":"10.1007","volume":"60","author":[{"given":"David M.","family":"Pariser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Mamelok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"issue":"4","key":"975_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.det.2014.06.006","volume":"32","author":"E Moraites","year":"2014","unstructured":"Moraites E, Vaughn OA, Hill S. Incidence and prevalence of hyperhidrosis. Dermatol Clin. 2014;32(4):457\u201365. https:\/\/doi.org\/10.1016\/j.det.2014.06.006.","journal-title":"Dermatol Clin."},{"key":"975_CR2","doi-asserted-by":"publisher","first-page":"f6800","DOI":"10.1136\/bmj.f6800","volume":"347","author":"RA Benson","year":"2013","unstructured":"Benson RA, Palin R, Holt PJ, Loftus IM. Diagnosis and management of hyperhidrosis. BMJ. 2013;347:f6800. https:\/\/doi.org\/10.1136\/bmj.f6800.","journal-title":"BMJ"},{"issue":"3","key":"975_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","volume":"81","author":"S Nawrocki","year":"2019","unstructured":"Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up. J Am Acad Dermatol. 2019;81(3):657\u201366. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.071.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"975_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","volume":"308","author":"J Doolittle","year":"2016","unstructured":"Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743\u20139. https:\/\/doi.org\/10.1007\/s00403-016-1697-9.","journal-title":"Arch Dermatol Res."},{"issue":"1","key":"975_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-016-0148-z","volume":"7","author":"DA Grabell","year":"2017","unstructured":"Grabell DA, Hebert AA. Current and emerging medical therapies for primary hyperhidrosis. Dermatol Ther (Heidelb). 2017;7(1):25\u201336. https:\/\/doi.org\/10.1007\/s13555-016-0148-z.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"975_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jaad.2016.07.001","volume":"75","author":"R Bahar","year":"2016","unstructured":"Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee TK, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol. 2016;75(6):1126\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.001.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"975_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12955-017-0693-x","volume":"15","author":"P Kamudoni","year":"2017","unstructured":"Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients\u2019 daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15(1):121. https:\/\/doi.org\/10.1186\/s12955-017-0693-x.","journal-title":"Health Qual Life Outcomes."},{"issue":"3","key":"975_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaad.2018.11.066","volume":"81","author":"S Nawrocki","year":"2019","unstructured":"Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol. 2019;81(3):669\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.066.","journal-title":"J Am Acad Dermatol."},{"issue":"11","key":"975_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s40261-019-00853-x","volume":"39","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Topical glycopyrronium tosylate in primary axillary hyperhidrosis: a profile of its use. Clin Drug Investig. 2019;39(11):1141\u20137. https:\/\/doi.org\/10.1007\/s40261-019-00853-x.","journal-title":"Clin Drug Investig."},{"issue":"1","key":"975_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","volume":"80","author":"DA Glaser","year":"2019","unstructured":"Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128\u201338. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.002.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"975_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40257-019-00446-6","volume":"20","author":"DA Glaser","year":"2019","unstructured":"Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, et al. A 44-week open-label study evaluating safety and efficacy of typical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593\u2013604. https:\/\/doi.org\/10.1007\/s40257-019-00446-6.","journal-title":"Am J Clin Dermatol."},{"issue":"1","key":"975_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40257-018-0395-0","volume":"20","author":"DM Pariser","year":"2019","unstructured":"Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135\u201345. https:\/\/doi.org\/10.1007\/s40257-018-0395-0.","journal-title":"Am J Clin Dermatol."},{"key":"975_CR13","unstructured":"Qbrexza\u00ae (glycopyrronium) cloth, 2.4%, for topical use [prescribing information]. Menlo Park (CA): Dermira Inc., 2018."},{"issue":"1","key":"975_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/pde.13723","volume":"36","author":"AA Hebert","year":"2019","unstructured":"Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatr Dermatol. 2019;36(1):89\u201399. https:\/\/doi.org\/10.1111\/pde.13723.","journal-title":"Pediatr Dermatol."},{"key":"975_CR15","unstructured":"International Hyperhidrosis Society. Primary axillary hyperhidrosis. 2018. https:\/\/www.sweathelp.org\/pdf\/Axillary_IHhS_Algorithm_2018.pdf. Accessed 03 Apr 2020."},{"key":"975_CR16","unstructured":"Cuvposa\u00ae (glycopyrrolate) oral solution [prescribing information]. Raleigh (NC): Merz Pharmaceuticals, LLC, 2015."},{"issue":"1","key":"975_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41687-019-0148-8","volume":"3","author":"LM Nelson","year":"2019","unstructured":"Nelson LM, DiBenedetti D, Pariser DM, Glaser DA, Hebert AA, Hofland H, et al. Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity. J Patient Rep Outcomes. 2019;3(1):59. https:\/\/doi.org\/10.1186\/s41687-019-0148-8.","journal-title":"J Patient Rep Outcomes."},{"key":"975_CR18","unstructured":"National Center for Biotechnology Information. PubChem database. Glycopyrrolate, CID=11693. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/11693. Accessed 17 June 2020."},{"key":"975_CR19","unstructured":"National Center for Biotechnology Information. PubChem database. Glycopyrronium tosylate, CID=112500546. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/112500546. Accessed 17 Jun 2020."},{"key":"975_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.taap.2019.03.016","volume":"370","author":"M Chabicovsky","year":"2019","unstructured":"Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Pharmacology, toxicology and clinical safety of glycopyrrolate. Toxicol Appl Pharmacol. 2019;370:154\u201369. https:\/\/doi.org\/10.1016\/j.taap.2019.03.016.","journal-title":"Toxicol Appl Pharmacol."},{"issue":"3","key":"975_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/pde.14135","volume":"37","author":"AA Hebert","year":"2020","unstructured":"Hebert AA, Glaser DA, Green L, Hull C, Cather J, Drew J, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analysis from a 44-week open-label extension study. Pediatr Dermatol. 2020;37(3):490\u20137. https:\/\/doi.org\/10.1111\/pde.14135.","journal-title":"Pediatr Dermatol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00975-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00975-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00975-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T03:37:52Z","timestamp":1620790672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00975-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00975-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"5 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies described in this article were funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"David M. Pariser was an investigator and consultant for Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, and received writing assistance. Edward L. Lain has received payment from the sponsor for work as a principal investigator, advisory board member, speaker, and consultant, but did not receive compensation for work related to the preparation and publication of this article. Richard D. Mamelok is a paid consultant to Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, and received financial support for reviewing data and for reviewing the manuscript. Janice Drew is a full-time employee and receives a salary from the sponsor of the study, Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Diane R. Mould is the president of Projections Research Inc., a consulting company for the pharmaceutical industry and was a paid consultant of Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company for the conduct of the data analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For the phase I and II clinical studies described in the article, the protocols, informed consent forms, and assent forms for subjects under legal adult age (phase I study only) were submitted to an institutional review board or independent ethics committee for review and approval before the start of the study. The studies were conducted in compliance with the principles of the International Conference on Harmonisation (E6 1997) Good Clinical Practice, US Food and Drug Administration guidelines, and the Declaration of Helsinki, 1964 (as amended in Edinburgh [2000]).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For the phase I and II clinical studies described in the article, informed consent was obtained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to the publication of the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, shares data related to these trials in peer-reviewed journals, medical congresses, and ClinicalTrials.gov. Individual patient data are not publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JD, DRM, and RDM had access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JD, DRM, and RDM provided the concept and design for the study. All authors were responsible for the acquisition, analysis, or interpretation of the data and the drafting and critical revision of the manuscript for important intellectual content. DRM and RDM conducted the data analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}